{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:09:34Z","timestamp":1791828574836,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"am","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002193","name":"Lupus Foundation of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002193","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","award":["00094818"],"award-info":[{"award-number":["00094818"]}],"id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R21AR069189"],"award-info":[{"award-number":["R21AR069189"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020070","name":"Morris and Alma Schapiro Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007747","name":"University of Utah","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011112","name":"UCB US","doi-asserted-by":"publisher","award":["UL1 TR 002538"],"award-info":[{"award-number":["UL1 TR 002538"]}],"id":[{"id":"10.13039\/100011112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ard.2025.02.012","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:12:37Z","timestamp":1744283557000},"page":"1011-1022","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single-arm, open-label, phase 2 trial"],"prefix":"10.1016","volume":"84","author":[{"given":"D. Ware","family":"Branch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1698-6209","authenticated-orcid":false,"given":"Marta M.","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Worden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl A.","family":"Laskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9239-5131","authenticated-orcid":false,"given":"Maria T.","family":"DeSancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna V.","family":"Landres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0995-9771","authenticated-orcid":false,"given":"Jason S.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8415-4175","authenticated-orcid":false,"given":"Haley S.","family":"Slosberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Minett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9113-7122","authenticated-orcid":false,"given":"Jane E.","family":"Salmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ard.2025.02.012_bib0001","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"10","key":"10.1016\/j.ard.2025.02.012_bib0002","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.ard.2025.02.012_bib0003","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/art.34402","article-title":"Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies","volume":"64","author":"Lockshin","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ard.2025.02.012_bib0004","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2015-000131","article-title":"Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results","volume":"3","author":"Yelnik","year":"2016","journal-title":"Lupus Sci Med"},{"issue":"5","key":"10.1016\/j.ard.2025.02.012_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2017.01.026","article-title":"Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study","volume":"216","author":"Saccone","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ard.2025.02.012_bib0006","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/rheumatology\/keaa203","article-title":"EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies","volume":"60","author":"Pregnolato","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.ard.2025.02.012_bib0007","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.41191","article-title":"2020 American College of Rheumatology Guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.ard.2025.02.012_bib0008","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ard.2025.02.012_bib0009","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/art.40136","article-title":"Emerging treatment models in rheumatology: antiphospholipid syndrome and pregnancy: pathogenesis to translation","volume":"69","author":"Abrahams","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2025.02.012_bib0010","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1084\/jem.200116116","article-title":"Complement C3 activation is required for antiphospholipid antibody-induced fetal loss","volume":"195","author":"Holers","year":"2002","journal-title":"J Exp Med"},{"issue":"11","key":"10.1016\/j.ard.2025.02.012_bib0011","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1172\/JCI200318817","article-title":"Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome","volume":"112","author":"Girardi","year":"2003","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.ard.2025.02.012_bib0012","doi-asserted-by":"crossref","first-page":"485","DOI":"10.4049\/jimmunol.174.1.485","article-title":"TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss","volume":"174","author":"Berman","year":"2005","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.ard.2025.02.012_bib0013","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.4049\/jimmunol.1402220","article-title":"Prevention of defective placentation and pregnancy loss by blocking innate immune pathways in a syngeneic model of placental insufficiency","volume":"195","author":"Gelber","year":"2015","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.ard.2025.02.012_bib0014","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases","volume":"86","author":"Ramos-Casals","year":"2007","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"10.1016\/j.ard.2025.02.012_bib0015","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","article-title":"Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials","volume":"43","author":"Charles","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ard.2025.02.012_bib0016","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.ard.2025.02.012_bib0017","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.autrev.2011.05.001","article-title":"Therapeutic blockade of TNF in patients with SLE-promising or crazy?","volume":"11","author":"Aringer","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.ard.2025.02.012_bib0018","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/art.22327","article-title":"Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus","volume":"56","author":"Aringer","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.ard.2025.02.012_bib0019","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/rheumatology\/kep270","article-title":"Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients","volume":"48","author":"Aringer","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.ard.2025.02.012_bib0020","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/acr.22516","article-title":"Proceedings from the American College of Rheumatology Reproductive Health Summit: the management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases","volume":"67","author":"Kavanaugh","year":"2015","journal-title":"Arthritis Care Res"},{"issue":"9","key":"10.1016\/j.ard.2025.02.012_bib0021","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/art.40508","article-title":"Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety database","volume":"70","author":"Clowse","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2025.02.012_bib0022","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","article-title":"Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study","volume":"77","author":"Mariette","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.02.012_bib0023","unstructured":"Full Prescribing Information for Cimzia: https:\/\/www.cimzia.com\/themes\/custom\/cimzia\/docs\/CIMZIA_full_prescribing_information.pdf"},{"issue":"1","key":"10.1016\/j.ard.2025.02.012_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2015.09.066","article-title":"Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study","volume":"214","author":"Kim","year":"2016","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ard.2025.02.012_bib0025","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ajog.2024.05.042","article-title":"Stillbirth: we can do better","volume":"231","author":"Silver","year":"2024","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ard.2025.02.012_bib0026","doi-asserted-by":"crossref","first-page":"153","DOI":"10.7326\/M14-2235","article-title":"Predictors of pregnancy outcomes in patients with lupus: a cohort study","volume":"163","author":"Buyon","year":"2015","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.ard.2025.02.012_bib0027","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.autrev.2014.12.010","article-title":"The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a survey of 247 consecutive cases","volume":"14","author":"Alijotas-Reig","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1016\/j.ard.2025.02.012_bib0028","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1177\/0961203320954520","article-title":"16th International Congress on Antiphospholipid Antibodies Task Force Report on obstetric antiphospholipid syndrome","volume":"29","author":"de Jes\u00fas","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.ard.2025.02.012_bib0029","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejogrb.2015.12.011","article-title":"Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT","volume":"197","author":"van Hoorn","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"5","key":"10.1016\/j.ard.2025.02.012_bib0030","article-title":"Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss","volume":"5","author":"Hamuly\u00e1k","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"1 Pt 1","key":"10.1016\/j.ard.2025.02.012_bib0031","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0002-9378(00)70500-X","article-title":"A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group","volume":"182","author":"Branch","year":"2000","journal-title":"Am J Obstet Gynecol"},{"issue":"2S","key":"10.1016\/j.ard.2025.02.012_bib0032","doi-asserted-by":"crossref","first-page":"S1171","DOI":"10.1016\/j.ajog.2020.08.040","article-title":"The role of statins in the prevention of preeclampsia","volume":"226","author":"Smith","year":"2022","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ard.2025.02.012_bib0033","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.semarthrit.2019.02.006","article-title":"Treatment of refractory poor aPL-related obstetric outcomes with TNF-alpha blockers: maternal-fetal outcomes in a series of 18 cases","volume":"49","author":"Alijotas-Reig","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.ard.2025.02.012_bib0034","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11926-021-01038-2","article-title":"Epidemiology of antiphospholipid syndrome in the general population","volume":"23","author":"Dabit","year":"2022","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"10.1016\/j.ard.2025.02.012_bib0035","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard-2023-224952","article-title":"Prevalence of clinically meaningful antiphospholipid antibodies in patients with systemic lupus erythematosus varies by race and ethnicity","volume":"83","author":"Yelnik","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2025.02.012_bib0036","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1160\/th15-06-0491","article-title":"The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment","volume":"115","author":"Sciascia","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ard.2025.02.012_bib0037","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.thromres.2021.08.004","article-title":"The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome","volume":"206","author":"Gerde","year":"2021","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.ard.2025.02.012_bib0038","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/art.42793","article-title":"Hydroxychloroquine in lupus pregnancy and risk of preeclampsia","volume":"76","author":"Rector","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.ard.2025.02.012_bib0039","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/acr.25386","article-title":"Hydroxychloroquine and pre-eclampsia in a diverse cohort of women with systemic lupus erythematosus","volume":"76","author":"Simard","year":"2024","journal-title":"Arthritis Care Res"},{"issue":"2","key":"10.1016\/j.ard.2025.02.012_bib0040","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001239","article-title":"Effect of hydroxychloroquine on pregnancy outcome in patients with SLE: a systematic review and meta-analysis","volume":"11","author":"Zhu","year":"2024","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.ard.2025.02.012_bib0041","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.preghy.2021.05.002","article-title":"Tumor necrosis factor-alpha blockade improves uterine artery resistance, maternal blood pressure, and fetal growth in placental ischemic rats","volume":"25","author":"Travis","year":"2021","journal-title":"Pregnancy Hypertens"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725002432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725002432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:12:01Z","timestamp":1774415521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725002432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0003496725002432"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.02.012","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single-arm, open-label, phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Alliance of Associations for Rheumatology (EULAR). Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}